Table 3 Univariate and multivariate analyses of overall survival
Univariate Analysis | |||
|---|---|---|---|
N | HR (95% CI) | p | |
Age (years) | 60 | 1.04 (0.99-1.10) | 0.16 |
PS 0 | 14 | 0.89 (0.32-2.44) | 0.81 |
PS 1-2 | 46 | 1 Ref. | |
Male | 36 | 1.09 (0.45-2.61) | |
Female | 24 | 1 Ref. | 0.85 |
Adenocarcinoma | 39 | 1 Ref. | |
Non-adenocarcinoma | 21 | 2.88 (1.21-6.87) | 0.02 |
Smoker | 22 | 0.96 (0.34-2.68) | |
Non-smoker | 27 | 1 Ref. | 0.93 |
EGFR mutated | 9 | 1 Ref. | |
EGFR wild-type | 41 | 1.19 (0.38-3.68) | 0.77 |
K-ras mutated | 10 | 0.81 (0.24-2.78) | 0.73 |
K-ras wild-type | 46 | 1 Ref. | |
Low BRCA1&AEG1 expression | 18 | 1 Ref. | |
High BRCA1&AEG1 expression | 17 | 2.80 (0.84-9.32) | 0.10 |
Other combinations of BRCA1&AEG1 expression | 25 | 1.84 (0.62-5.41) | 0.27 |
1 treatment line | 18 | 1 Ref. | |
≥ 2 treatment lines | 42 | 0.44 (0.16-1.22) | 0.12 |
1 metastatic site | 30 | 1 Ref. | |
≥ 2 metastatic sites | 24 | 1.46 (0.57-3.72) | 0.43 |
Bone metastases | 23 | 3.06 (1.15-8.16) | 0.03 |
No bone metastases | 31 | 1 Ref. | |
Brain metastases | 10 | 1 Ref. | |
No brain metastases | 44 | 1.86 (0.54-6.48) | 0.33 |
Multivariate Analysis | |||
Adenocarcinoma | 36 | 1 Ref. | |
Non-adenocarcinoma | 18 | 3.17 (1.21-8.31) | 0.02 |
1 treatment line | 14 | 7.22 (1.96-26.64) | 0.003 |
≥ 2 treatment lines | 40 | 1 Ref. | |
Bone metastases | 23 | 4.73 (1.58-14.17) | 0.005 |
No bone metastases | 31 | 1 Ref. | |